Muhammad Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muhammad Ali has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Ghulam Mustafa
Affiliation Department of Biochemistry, Government College University Faisalabad, Faisalabad Pakistan
6 shared publications - Ali Sharif
Department of Pharmacology, Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Pakistan
4 shared publications - Bushra Akhtar
Department of Pharmacy, University of Agriculture Faisalabad, Faisalabad, Pakistan
3 shared publications - Arifa Mehreen
University of Agriculture Faisalabad
2 shared publications Bushra Akhtar
2 shared publicationsMahnoor Yamin
Department of Zoology, Wildlife and Fisheries, Faculty of Sciences, University of Agriculture Faisalabad (UAF), Faisalabad 38040, Pakistan
2 shared publications
Latest Publications
- 28 October 2026
- Published by Springer Nature in Emergent Materials
- Vol. 9 (11) , 271
Towards next-generation hydrogen sensors: Material innovations, intelligent sensing, and future challenges
- 28 October 2026
- Published by Springer Nature in Emergent Materials
- Vol. 9 (11) , 271
Towards next-generation hydrogen sensors: Material innovations, intelligent sensing, and future challenges
- 24 July 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (11) , 8482-8507
Antidiabetic Effect of Coronopus Didymus, Azadirachta Indica and Their Active Compound Quercetin Against STZ-NA Induced Diabetes Mice Models
- 24 July 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (11) , 8482-8507
Antidiabetic Effect of Coronopus Didymus, Azadirachta Indica and Their Active Compound Quercetin Against STZ-NA Induced Diabetes Mice Models
- 27 March 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 3293-3312
α-Pinene alleviates inflammatory responses and oxidative stress in freund’s complete adjuvant induced arthritic rat model and associated risk factors of atherosclerosis
Arthritis is characterized by joint inflammation that can lead to severe bone erosions and affects 0.1 to 2.0% of people globally. People with RA are 1.5 times more likely to develop CVDs including atherosclerosis. The goal of the current investigation was to determine the effect of α-Pinene in FCA induced RA and associated atherosclerosis in rat model. In an experimental model of 23 days, 0.15mL FCA was administered for RA induction. Treatment drug α-Pinene was administered in different doses (25mg/kg, 50mg/kg and 100mg/kg) and a standard methotrexate (0.75mg/kg). Parameters like body weight, paw thickness, arthritic scoring, joint stiffness, hematological, serological, biochemical and inflammatory markers (DDAH, CST, TNF-α, IL-6, IL-1β) were analyzed. The results showed that treatment with α-Pinene, especially its combination with MSTD significantly (p < 0.001) ameliorates body weight, paw thickness, arthritic scoring, joint stiffness, hematological, lipid profile, and restored the endogenous anti-oxidant (SOD, CAT, GSH, MDA and Nitrite) activities. α-PNHD + MSTD also significantly (p < 0.001) reduced ADMA, pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and increased DDAH or CST expression. Histopathological analysis showed that α-PNHD + MSTD significantly (p < 0.001) alleviated bone and cartilage erosion, pannus formation, synovial hyperplasia and vascular congestion. Thus, α-Pinene’s anti-inflammatory and anti-oxidant properties suggests its therapeutic effectiveness in RA and its associated risk of atherosclerosis. Its combination with MSTD suggests promising therapeutic profile and warrants for further research and development in the field of rheumatology.
- 27 March 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 3293-3312
α-Pinene alleviates inflammatory responses and oxidative stress in freund’s complete adjuvant induced arthritic rat model and associated risk factors of atherosclerosis
Arthritis is characterized by joint inflammation that can lead to severe bone erosions and affects 0.1 to 2.0% of people globally. People with RA are 1.5 times more likely to develop CVDs including atherosclerosis. The goal of the current investigation was to determine the effect of α-Pinene in FCA induced RA and associated atherosclerosis in rat model. In an experimental model of 23 days, 0.15mL FCA was administered for RA induction. Treatment drug α-Pinene was administered in different doses (25mg/kg, 50mg/kg and 100mg/kg) and a standard methotrexate (0.75mg/kg). Parameters like body weight, paw thickness, arthritic scoring, joint stiffness, hematological, serological, biochemical and inflammatory markers (DDAH, CST, TNF-α, IL-6, IL-1β) were analyzed. The results showed that treatment with α-Pinene, especially its combination with MSTD significantly (p < 0.001) ameliorates body weight, paw thickness, arthritic scoring, joint stiffness, hematological, lipid profile, and restored the endogenous anti-oxidant (SOD, CAT, GSH, MDA and Nitrite) activities. α-PNHD + MSTD also significantly (p < 0.001) reduced ADMA, pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and increased DDAH or CST expression. Histopathological analysis showed that α-PNHD + MSTD significantly (p < 0.001) alleviated bone and cartilage erosion, pannus formation, synovial hyperplasia and vascular congestion. Thus, α-Pinene’s anti-inflammatory and anti-oxidant properties suggests its therapeutic effectiveness in RA and its associated risk of atherosclerosis. Its combination with MSTD suggests promising therapeutic profile and warrants for further research and development in the field of rheumatology.
- 6 February 2026
- Published by Elsevier in Tissue and Cell
- Vol. 100, 103374
Protective effects of linagliptin and tenofovir disoproxil fumarate against APAP-induced acute liver injury: A biochemical, histological, and computational study
- 6 February 2026
- Published by Elsevier in Tissue and Cell
- Vol. 100, 103374
Protective effects of linagliptin and tenofovir disoproxil fumarate against APAP-induced acute liver injury: A biochemical, histological, and computational study
- 12 April 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (6) , 3119-3134
N-Dimethyl chalcone facilitated augmentation of IL-10 and diminution of TNF-α, IL-1β, IL-6, NFκB, and COX-2 in FCA-induced arthritic rat model
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and chronic pain due to the degradation of subchondral bone and the loss of cartilage function. The present study was designed to evaluate the activity of 1N,N-dimethyl chalcone (DGCHAL) against RA. A primary 28-day investigation was conducted on adjuvant-induced arthritic rats with DGCHAL (10 mg/kg, 20 mg/kg, and 30 mg/kg) and methotrexate (STDMTX). The therapeutic effect was estimated on the basis of measurements of paw diameter, fluctuations in body weight, oxidative stress biomarkers, and hematological parameters. In addition, the study sought to quantify the expression of key cytokines, including TNFα, IL-6, IL-10, IL-1β, and NFκβ, using qRT-PCR and ELISA techniques. Treatment with DGCHAL significantly restored the paw volume, body weight, arthritis-induced anemia, and leukocyte count. The tested compound remarkably downregulated the expression of COX-2, TNFα, IL-6, IL-1β, and NFκB and upregulated the expression of IL-10. The treatment groups increased the activities of SOD, CAT, and GSH, whereas they reduced the formation of MDA and NO as compared to the arthritic group. These findings provide an evident basis for the anti-arthritic potential of DGCHAL in a chronic arthritis rat model and should be further studied for dosage form design.
- 12 April 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (6) , 3119-3134
N-Dimethyl chalcone facilitated augmentation of IL-10 and diminution of TNF-α, IL-1β, IL-6, NFκB, and COX-2 in FCA-induced arthritic rat model
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and chronic pain due to the degradation of subchondral bone and the loss of cartilage function. The present study was designed to evaluate the activity of 1N,N-dimethyl chalcone (DGCHAL) against RA. A primary 28-day investigation was conducted on adjuvant-induced arthritic rats with DGCHAL (10 mg/kg, 20 mg/kg, and 30 mg/kg) and methotrexate (STDMTX). The therapeutic effect was estimated on the basis of measurements of paw diameter, fluctuations in body weight, oxidative stress biomarkers, and hematological parameters. In addition, the study sought to quantify the expression of key cytokines, including TNFα, IL-6, IL-10, IL-1β, and NFκβ, using qRT-PCR and ELISA techniques. Treatment with DGCHAL significantly restored the paw volume, body weight, arthritis-induced anemia, and leukocyte count. The tested compound remarkably downregulated the expression of COX-2, TNFα, IL-6, IL-1β, and NFκB and upregulated the expression of IL-10. The treatment groups increased the activities of SOD, CAT, and GSH, whereas they reduced the formation of MDA and NO as compared to the arthritic group. These findings provide an evident basis for the anti-arthritic potential of DGCHAL in a chronic arthritis rat model and should be further studied for dosage form design.
- Open Access
- 21 January 2025
- Published by Springer Nature in Inflammation
- Vol. 48 (5) , 2874-2895
Mitigation of Neuroinflammation and Oxidative Stress in Rotenone-Induced Parkinson Mouse Model through Liposomal Coenzyme-Q10 Intervention: A Comprehensive In-vivo Study
Parkinson's disease (PD) stands as the sec most prevalent incapacitating neurodegenerative disorder characterized by deterioration of dopamine-producing neurons in the substantia nigra. Coenzyme Q10 (CoQ10) has garnered attention as a potential antioxidant, anti-inflammatory agent and enhancer of mitochondrial complex-I activity. This study aimed to examine and compare the effectiveness of liposomal and non-encapsulated CoQ10 in rotenone induced-PD mouse model over a 21-day treatment duration. 30 mice were divided into 5 equal groups: Group I (mice receiving normal saline), Group II (rotenone was administered to mice), Group III (standard CoQ10 was given to mice), Group IV (mice were treated with non-encapsulated CoQ10) and Group V (mice were treated with CoQ10 Liposomes). Motor performance, the preservation of dopaminergic neurons, levels of neuroinflammation, oxidative stress, neurotransmitter levels, RT-qPCR analysis of PD-linked genes and histopathology were evaluated. The Liposomal CoQ10 group exhibited superior outcomes in behavioral tests such as reduced anxiety in the open field test, enhanced balance and coordination in beam balance test and improved cognitive performance in Y-maze test. Liposomal Coenzyme Q10 displayed pronounced antioxidative effects, evidenced by a significant (p < 0.001) increase in superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) activities. In contrast, the non-encapsulated CoQ10 group showed a delayed response in mitigating the inflammation and oxidative stress. CoQ10 Liposomes demonstrated superior efficacy (p < 0.0001) in restoring dopamine and noradrenaline levels, reducing acetylcholinesterase activity, and downregulating Synuclein Alpha (SNCA) gene expression (0.722-fold change) compared to oral CoQ10, highlighting its potential in suppressing PD symptoms. The results of this study indicated that the liposomal CoQ10 effectively averted motor impairments, memory lapses, oxidative stress, as well as neuroinflammation triggered by rotenone.
- 21 January 2025
- Published by Springer Nature in Inflammation
- Vol. 48 (5) , 2874-2895
Open AccessMitigation of Neuroinflammation and Oxidative Stress in Rotenone-Induced Parkinson Mouse Model through Liposomal Coenzyme-Q10 Intervention: A Comprehensive In-vivo Study
Parkinson's disease (PD) stands as the sec most prevalent incapacitating neurodegenerative disorder characterized by deterioration of dopamine-producing neurons in the substantia nigra. Coenzyme Q10 (CoQ10) has garnered attention as a potential antioxidant, anti-inflammatory agent and enhancer of mitochondrial complex-I activity. This study aimed to examine and compare the effectiveness of liposomal and non-encapsulated CoQ10 in rotenone induced-PD mouse model over a 21-day treatment duration. 30 mice were divided into 5 equal groups: Group I (mice receiving normal saline), Group II (rotenone was administered to mice), Group III (standard CoQ10 was given to mice), Group IV (mice were treated with non-encapsulated CoQ10) and Group V (mice were treated with CoQ10 Liposomes). Motor performance, the preservation of dopaminergic neurons, levels of neuroinflammation, oxidative stress, neurotransmitter levels, RT-qPCR analysis of PD-linked genes and histopathology were evaluated. The Liposomal CoQ10 group exhibited superior outcomes in behavioral tests such as reduced anxiety in the open field test, enhanced balance and coordination in beam balance test and improved cognitive performance in Y-maze test. Liposomal Coenzyme Q10 displayed pronounced antioxidative effects, evidenced by a significant (p < 0.001) increase in superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) activities. In contrast, the non-encapsulated CoQ10 group showed a delayed response in mitigating the inflammation and oxidative stress. CoQ10 Liposomes demonstrated superior efficacy (p < 0.0001) in restoring dopamine and noradrenaline levels, reducing acetylcholinesterase activity, and downregulating Synuclein Alpha (SNCA) gene expression (0.722-fold change) compared to oral CoQ10, highlighting its potential in suppressing PD symptoms. The results of this study indicated that the liposomal CoQ10 effectively averted motor impairments, memory lapses, oxidative stress, as well as neuroinflammation triggered by rotenone.
- Open Access
- 8 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (6) , 757
Quercetin and Kaempferol as Multi-Targeting Antidiabetic Agents against Mouse Model of Chemically Induced Type 2 Diabetes
Diabetes, a multifactorial metabolic disorder, demands the discovery of multi-targeting drugs with minimal side effects. This study investigated the multi-targeting antidiabetic potential of quercetin and kaempferol. The druggability and binding affinities of both compounds towards multiple antidiabetic targets were explored using pharmacokinetic and docking software (AutoDock Vina 1.1.2). Our findings showed that quercetin and kaempferol obey Lipinski’s rule of five and exhibit desirable ADMET (absorption, distribution, metabolism excretion, and toxicity) profiles. Both compounds showed higher binding affinities towards C-reactive protein (CRP), interleukin-1 (IL-1), dipeptidyl peptidase-4 (DPP-IV), peroxisome proliferator-activated receptor gamma (PPARG), protein tyrosine phosphatase (PTP), and sodium–glucose co-transporter-1 (SGLT-1) compared to metformin (the positive control). Both quercetin and kaempferol inhibited α-amylase activity (in vitro) up to 20.30 ± 0.49 and 37.43 ± 0.42%, respectively. Their oral supplementation significantly reduced blood glucose levels (p < 0.001), improved lipid profile (p < 0.001), and enhanced total antioxidant status (p < 0.01) in streptozotocin–nicotinamide (STZ-NA)-induced diabetic mice. Additionally, both compounds significantly inhibited the proliferation of Huh-7 and HepG2 (cancer cells) (p < 0.0001) with no effect on the viability of Vero cell line (non-cancer). In conclusion, quercetin and kaempferol demonstrated higher binding affinities towards multiple targets than metformin. In vitro and in vivo antidiabetic potential along with the anticancer activities of both compounds suggest promise for further development in diabetes management. The combination of both drugs did not show a synergistic effect, possibly due to their same target on the receptors.
- 8 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (6) , 757
Open AccessQuercetin and Kaempferol as Multi-Targeting Antidiabetic Agents against Mouse Model of Chemically Induced Type 2 Diabetes
Diabetes, a multifactorial metabolic disorder, demands the discovery of multi-targeting drugs with minimal side effects. This study investigated the multi-targeting antidiabetic potential of quercetin and kaempferol. The druggability and binding affinities of both compounds towards multiple antidiabetic targets were explored using pharmacokinetic and docking software (AutoDock Vina 1.1.2). Our findings showed that quercetin and kaempferol obey Lipinski’s rule of five and exhibit desirable ADMET (absorption, distribution, metabolism excretion, and toxicity) profiles. Both compounds showed higher binding affinities towards C-reactive protein (CRP), interleukin-1 (IL-1), dipeptidyl peptidase-4 (DPP-IV), peroxisome proliferator-activated receptor gamma (PPARG), protein tyrosine phosphatase (PTP), and sodium–glucose co-transporter-1 (SGLT-1) compared to metformin (the positive control). Both quercetin and kaempferol inhibited α-amylase activity (in vitro) up to 20.30 ± 0.49 and 37.43 ± 0.42%, respectively. Their oral supplementation significantly reduced blood glucose levels (p < 0.001), improved lipid profile (p < 0.001), and enhanced total antioxidant status (p < 0.01) in streptozotocin–nicotinamide (STZ-NA)-induced diabetic mice. Additionally, both compounds significantly inhibited the proliferation of Huh-7 and HepG2 (cancer cells) (p < 0.0001) with no effect on the viability of Vero cell line (non-cancer). In conclusion, quercetin and kaempferol demonstrated higher binding affinities towards multiple targets than metformin. In vitro and in vivo antidiabetic potential along with the anticancer activities of both compounds suggest promise for further development in diabetes management. The combination of both drugs did not show a synergistic effect, possibly due to their same target on the receptors.
- Open Access
Screening of Multitarget Compounds against Acetaminophen Hepatic Toxicity Using In Silico, In Vitro, and In Vivo Approaches
Combination therapy and multitarget drugs have recently attracted much attention as promising tools to fight against many challenging diseases and, thus, represent a new research focus area. The aim of the current project was to screen multitarget compounds and to study their individual and combined effects on acetaminophen-induced liver injury. In this study, 2 of the best hepatoprotective multitargeting compounds were selected from a pool of 40 major compounds present in Curcuma longa and Cinnamomum zeylanicum by using molecular docking, ADMET profiling, and Pfizer’s rule of five. The two selected compounds, quercetin and curcumin, showed a high binding affinity for the CYP2E1 enzyme, MAPK, and TLR4 receptors that contribute to liver injury. The candidates caused the decreased viability of cancer cell lines (HepG2 and Huh7) but showed no effect on a normal cell line (Vero). Examination of biochemical parameters (ALT, AST, ALP, and bilirubin) showed the hepatoprotective effect of the candidate drugs in comparison with the control group, which was confirmed by histological findings. Taken together, quercetin and curcumin not only satisfied the drug-like assessment criterion and proved to be multitargeting by preventing liver damage but also showed anticancer activities.
Open AccessScreening of Multitarget Compounds against Acetaminophen Hepatic Toxicity Using In Silico, In Vitro, and In Vivo Approaches
Combination therapy and multitarget drugs have recently attracted much attention as promising tools to fight against many challenging diseases and, thus, represent a new research focus area. The aim of the current project was to screen multitarget compounds and to study their individual and combined effects on acetaminophen-induced liver injury. In this study, 2 of the best hepatoprotective multitargeting compounds were selected from a pool of 40 major compounds present in Curcuma longa and Cinnamomum zeylanicum by using molecular docking, ADMET profiling, and Pfizer’s rule of five. The two selected compounds, quercetin and curcumin, showed a high binding affinity for the CYP2E1 enzyme, MAPK, and TLR4 receptors that contribute to liver injury. The candidates caused the decreased viability of cancer cell lines (HepG2 and Huh7) but showed no effect on a normal cell line (Vero). Examination of biochemical parameters (ALT, AST, ALP, and bilirubin) showed the hepatoprotective effect of the candidate drugs in comparison with the control group, which was confirmed by histological findings. Taken together, quercetin and curcumin not only satisfied the drug-like assessment criterion and proved to be multitargeting by preventing liver damage but also showed anticancer activities.
- Open Access
In Silico Analysis of Honey Bee Peptides as Potential Inhibitors of Capripoxvirus DNA-Directed RNA Polymerase
The genus Capripoxvirus belongs to the Poxviridae family. The sheeppox, goatpox, and lumpy skin disease viruses are three species of this genus with 96% identity in their genomes. These are financially devastating viral infections among cattle, which cause a reduction in animal products and lead to a loss in livestock industries. In the current study, the phylogenetic analysis was carried out to reveal the evolutionary relationships of Capripoxvirus species (i.e., sheeppox virus (SPPV), goatpox virus (GTPV), and lumpy skin disease virus (LSDV)) with other viruses from the Poxviridae family with >96% query coverage to find the similarity index among all members. The three viruses (i.e., SPPV, GTPV, and LSDV) joined the clade of Capripoxvirus of the Poxviridae family in the phylogenetic tree and exhibited close evolutionary relationships. The multiple sequence alignment using ClustalOmega revealed significant variations in the protein sequences of the DNA-dependent RNA polymerase of SPPV, GTPV, and LSDV. The three-dimensional structures of five selected bee peptides and DNA-directed RNA polymerase of SPPV, GTPV, and LSDV were predicted using trRosetta and I-TASSER and used for molecular docking and simulation studies. The protein–protein docking was carried out using HADDOCK server to explore the antiviral activity of peptides as honey bee proteins against SPPV, GTPV, and LSDV. In total, five peptides were docked to DNA-directed RNA polymerase of these viruses. The peptides mellitin and secapin-1 displayed the lowest binding scores (−106.9 +/− 7.2 kcal/mol and −101.4 +/− 11.3 kcal/mol, respectively) and the best patterns with stable complexes. The molecular dynamics simulation indicated that the complex of protein DNA-dependent RNA polymerase and the peptide melittin stayed firmly connected and the peptide binding to the receptor protein was stable. The findings of this study provide the evidence of bee peptides as potent antimicrobial agents against sheeppox, goatpox, and lumpy skin disease viruses with no complexity.
Open AccessIn Silico Analysis of Honey Bee Peptides as Potential Inhibitors of Capripoxvirus DNA-Directed RNA Polymerase
The genus Capripoxvirus belongs to the Poxviridae family. The sheeppox, goatpox, and lumpy skin disease viruses are three species of this genus with 96% identity in their genomes. These are financially devastating viral infections among cattle, which cause a reduction in animal products and lead to a loss in livestock industries. In the current study, the phylogenetic analysis was carried out to reveal the evolutionary relationships of Capripoxvirus species (i.e., sheeppox virus (SPPV), goatpox virus (GTPV), and lumpy skin disease virus (LSDV)) with other viruses from the Poxviridae family with >96% query coverage to find the similarity index among all members. The three viruses (i.e., SPPV, GTPV, and LSDV) joined the clade of Capripoxvirus of the Poxviridae family in the phylogenetic tree and exhibited close evolutionary relationships. The multiple sequence alignment using ClustalOmega revealed significant variations in the protein sequences of the DNA-dependent RNA polymerase of SPPV, GTPV, and LSDV. The three-dimensional structures of five selected bee peptides and DNA-directed RNA polymerase of SPPV, GTPV, and LSDV were predicted using trRosetta and I-TASSER and used for molecular docking and simulation studies. The protein–protein docking was carried out using HADDOCK server to explore the antiviral activity of peptides as honey bee proteins against SPPV, GTPV, and LSDV. In total, five peptides were docked to DNA-directed RNA polymerase of these viruses. The peptides mellitin and secapin-1 displayed the lowest binding scores (−106.9 +/− 7.2 kcal/mol and −101.4 +/− 11.3 kcal/mol, respectively) and the best patterns with stable complexes. The molecular dynamics simulation indicated that the complex of protein DNA-dependent RNA polymerase and the peptide melittin stayed firmly connected and the peptide binding to the receptor protein was stable. The findings of this study provide the evidence of bee peptides as potent antimicrobial agents against sheeppox, goatpox, and lumpy skin disease viruses with no complexity.